Skip to main content
Meeting Highlights
ASH Highlights
Mosunetuzumab, a Bispecific Antibody, Induces Deep Remissions in Relapsed or Refractory Follicular Lymphoma
Read More
FDA Updates
Enobosarm Granted Fast-Track FDA Review for AR- and ER-Positive, HER2-Negative Metastatic Breast Cancer
Read More
FDA Updates
FDA Grants Gedatolisib, a Dual PI3K and mTOR Inhibitor, Fast-Track Review for ER-Positive, HER2-Negative Breast Cancer
Read More
FDA Updates
Rituximab plus Chemotherapy FDA Approved for Several Pediatric Hematologic Malignancies
Read More
FDA Updates
Keytruda Now Approved for the Adjuvant Treatment of Stage IIB/IIC Melanoma
Read More
FDA Updates
Orencia First Drug FDA Approved for the Prevention of Acute Graft-versus-Host Disease
Read More
FDA Updates
Kimmtrak, a Bispecific CD3 T-Cell Engager, First FDA-Approved Drug for Unresectable or Metastatic Uveal Melanoma
Read More
Meeting Highlights
ASH Highlights, Venetoclax
Time-Limited Venetoclax Combinations Superior to Chemoimmunotherapy in Fit Patients with CLL
Read More
Meeting Highlights
ASH Highlights
Isatuximab plus RVd Regimen Achieves Highest Rates of No MRD in Patients with Multiple Myeloma
Read More
Original Research, Chemotherapy, Practical Issues in Pharmacy Management
Evaluation of the Safety and Potential Time-Savings of Subcutaneous Rituximab Administration in a Single Cancer Center
Ashka Patel, PharmD, BCOP, Chirag Patel, MS, Caroline M. Mejías-De Jesús, PharmD, BCOP
Ashka Patel, PharmD, BCOP; Chirag Patel, MS; Caroline M. Mejías-De Jesús, PharmD, BCOP
Read More
Page 59 of 199
Results 581 - 590 of 1986